Cost–effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. (7th June 2018)

• Record Type: Journal Article
• Authors: Zhu, Jun; He, Wei; Ye, Ming; Fu, Jie; Chu, Yun-Bo; Zhao, Yi-Yang; Zhang, Yan-Jun; Kuo, David; Wu, Bin
• Is Part Of: Future oncology. Volume 14:Number 27(2018)
• Page Start: 2833
• Page End: 2840
• Publication Date: 2018-06-07
• Subjects: afatinib -- cost–effectiveness -- erlotinib -- squamous cell carcinoma of the lung; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0321
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To investigate the cost–effectiveness of afatinib and erlotinib as second-line therapy for advanced squamous cell carcinoma of the lung.Materials & methods: A decision-analytic model was developed for projecting the economic outcomes. Clinical parameters and utilities were from the LUX-Lung 8 trial. Costs were mainly estimated from the Chinese health system. The outcome was the incremental cost–effectiveness ratio.Results: The afatinib strategy generated additional 0.154 quality-adjusted life-years compared with erlotinib, with incremental costs of ¥16, 852. Relative to erlotinib, afatinib resulted in an incremental cost–effectiveness ratio of ¥109, 429 per quality-adjusted life-year gained. The overall survival time of afatinib had a considerable impact on the model outcomes.Conclusion: Afatinib is a cost-effective treatment option compared with erlotinib in patients with squamous cell carcinoma.